CD19 and B-cell chronic lymphocytic leukemia: Liu et al. [225] conducted a phase I/II trial on B-NHL and CLL patients using HLA-mismatched, cord-blood-derived anti-CD19 CAR NKs, showing no CRS, ICANS, or GVHD and consistent response rates, especially in indolent diseases.